



## **PRESS RELEASE**

### **EDEN BIODESIGN RESTRUCTURES ITS EXECUTIVE MANAGEMENT TEAM**

#### **Dr Derek Ellison appointed Chief Operating Officer as business operations expand**

**Liverpool, UK; 28 January 2009:** Eden Biodesign, an expert provider of biopharmaceutical process development and cGMP manufacturing services, today announced a management restructure to include the appointment of Dr Derek Ellison as Chief Operating Officer (COO). The restructure results in changes in responsibility for seven executive and senior management members, to support growing demand as Eden continues to expand globally.

Newly appointed COO, Dr Derek Ellison (Co-Founder of Eden and previously VP Development and Manufacturing) has taken the position at a time when Eden Biodesign branches further into the US. "I am extremely excited to take on the role of COO" Derek Ellison said, "being a Co-Founder in Eden, I have witnessed the company rise and develop, and am extremely proud of our move into new markets, while retaining our excellent reputation."

Dr Anita Bate, (Co-Founder of Eden) will take up the role of Chief Scientific Officer from Science Director. Anita's responsibilities will include managing a dedicated transatlantic team of people tasked with looking at new opportunities for Eden, exploring and evaluating new technologies.

Team restructures are also taking place globally, as Dr Phil Ball moves from the UK over to the US offices. Phil will take up the role of Technical Director from Analytical and Purification Development Manager, allowing Phil to support Roger Lias, President of Eden Biodesign, Inc. (the US subsidiary of Eden), as US business continues to expand.

The management team has been further strengthened, resulting in promotion and changes in responsibility for four members of staff. Dr David Simpson moves to become Process Development Manager, Dr Mandy Shipman takes up the role of Biopharm Development Consultant, Gina Wenham takes on responsibility for the Analytical Development team alongside Quality Control and Alison Justice has been promoted to QA Director.



Dr Crawford Brown, CEO and founder of Eden Biodesign commented: “We are delighted to announce these strategic changes to the executive and senior management team, which will maintain Eden’s position of leadership in the bioprocessing marketplace and which demonstrates our commitment to US development and our international focus as demand continues to grow”.

Eden Biodesign Inc, the US subsidiary, last week relocated to North Carolina’s biotech hub, Research Triangle Park, North Carolina.

### **Ends**

For further information contact:

Karen Slack, De Facto Communications Ltd  
+44 (0)207 861 3838  
Email [K.Slack@defacto.com](mailto:K.Slack@defacto.com)

### **Notes to editors:**

#### **Eden Biodesign**

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides ‘state of the art’ development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of ‘Good Science’ at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit [www.edenbiodesign.com](http://www.edenbiodesign.com).

Contact details for Eden Biodesign, Ltd., National Biomanufacturing Centre, Estuary Banks, Estuary Commerce Park, Speke Road, Liverpool, UK